Biogen and Eisai have also kicked off a rolling application for their second amyloid antibody lecanemab – ahead of the results of clinical data from the pivotal CLARITY AD study, also due in the ...

The life sciences industry has recently been rocked by dramatic changes in how healthcare is provided, how drugs are developed and researched, the technologies available that enable companies to ...

That something is a medication called lecanemab. DENT administers it in its infusion center, through an IV only to patients with an early diagnosis of Alzheimer's. Center leaders say the drug attacks ...